News & Updates
CMS Finalizes New Medicare Coverage Pathway for FDA-Designated Breakthrough Devices
January 20, 2021 — Under the new rule, SOLVD Health’s breakthrough-designated devices for opioid use disorder and colon cancer will receive national Medicare coverage the day of FDA market authorization.
SOLVD Health Prepares to Launch Clinical Study of Non-Invasive Colorectal Cancer Screening Test
January 6, 2021 — The PREVENT clinical trial will enroll up to 12,000 individuals to validate the test, LifeKit Prevent, for the detection of colorectal cancer and adenomas. Subjects will include adults at average-risk for colorectal cancer between the ages of 45 and 84.
SOLVD Health Receives CE Mark for Genetic Risk Assessment for Opioid Use Disorder
December 7, 2020 — This new genetic test is designed to analyze 15 genetic variants involved in the brain reward pathway to identify patients who may be at increased risk for opioid addiction. The CE mark is legally required to place a device on the market in the European Union (EU).
Prescient Medicine Holdings is Now SOLVD Health
December 1, 2020 — The new name and brand reflect the company’s mission to solve some of healthcare’s biggest challenges through preventative health solutions that combine genetics-based patient insights with cutting-edge technologies.
Management Solutions for Opioid Epidemic Are Similar to Management of the COVID-19 Pandemic
September 21, 2020 — Pharmacy Times® interviewed Keri Donaldson, medical director and CEO of Prescient Medicine, about the effects of the current coronavirus disease 2019 (COVID-19) pandemic on the ongoing opioid epidemic in the United States.
Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening
June 2, 2020 — The aim of the collaboration is to study microbial biomarkers to identify the presence of precancerous adenomas and carcinomas in the colon.
Prescient Medicine and Erasmus MC Partner to Study Opioid Addiction Risk
December 10, 2019 — The partnership will center on Prescient Medicine’s novel genetic testing technology designed to objectively assess an individual’s risk of opioid addiction prior to opioid exposure.
FDA Grants Breakthrough Device Designation to Metabiomics Test for Early Detection of Colon Polyps and Colon Cancer
September 4, 2019 — This Breakthrough Device designation is the first designation for a non-invasive diagnostic test that is designed to detect pre-cancerous polyps, as well as early-stage carcinomas.
Prescient Medicine Holdings Inc. Acquires AutoGenomics Inc.
April 23, 2019 — The acquisition of AutoGenomics will enable Prescient Medicine to advance the development and commercialization of a novel diagnostic test for the identification of patients who may be at risk for opioid use disorder (OUD).